NDC 0002-7669

CYRAMZA

Ramucirumab

CYRAMZA is a Intravenous Solution in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Ramucirumab.

• Product ID: 0002-7669_07c65766-dcfd-4196-bd57-b21abf44815d
• NDC: 0002-7669
• Product Type: Human Prescription Drug
• Proprietary Name: CYRAMZA
• Generic Name: Ramucirumab
• Dosage Form: Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2014-04-21
• Marketing Category: BLA / BLA
• Application Number: BLA125477
• Labeler Name: Eli Lilly and Company
• Substance Name: RAMUCIRUMAB
• Active Ingredient Strength: 10 mg/mL
• Pharm Classes: VEGFR2 Inhibitors [MoA], Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0002-7669-01

1 VIAL, SINGLE-DOSE in 1 CARTON (0002-7669-01) > 10 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2014-04-21
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0002-7669-01 [00002766901]

CYRAMZA SOLUTION

• Marketing Category: BLA
• Application Number: BLA125477
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2014-04-21

Drug Details

Active Ingredients

Ingredient	Strength
RAMUCIRUMAB	10 mg/mL

OpenFDA Data

• SPL SET ID: c6080942-dee6-423e-b688-1272c2ae90d4
• Manufacturer:
  • Eli Lilly and Company
• UNII:
  • D99YVK4L0X
• RxNorm Concept Unique ID - RxCUI:
  • 1657777
  • 1657781
  • 1657775
  • 1657780
• UPC Code:
  • 0300027669014

Pharmacological Class

• Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]
• VEGFR2 Inhibitors [MoA]

NDC Crossover Matching brand name "CYRAMZA" or generic name "Ramucirumab"

NDC	Brand Name	Generic Name
0002-7669	CYRAMZA	ramucirumab
0002-7678	CYRAMZA	ramucirumab